Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, China.
Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, China.
FEBS Open Bio. 2021 Apr;11(4):1223-1236. doi: 10.1002/2211-5463.13082. Epub 2021 Mar 17.
Iron loading has been reported to be a common stress in the development of cells, and this might be related to bone loss and osteoporosis. Astragaloside IV (ASI-IV), a pure compound derived from Radix Astragali, has been reported to exhibit cardioprotective, anti-inflammatory, antioxidant, antiasthmatic and anticancer effects. The aim of this study was to investigate whether ASI-IV could reverse iron loading-induced inhibition of cell viability, proliferation, pluripotency and osteogenesis and promote adipogenesis of bone marrow mesenchymal stem cells (BMSCs). Ferric ammonium citrate (FAC) was used to stimulate iron loading conditions. ASI-IV was observed to ameliorate the FAC-induced reduction of cell viability, proliferation, pluripotency and osteogenesis of BMSCs. In addition, ASI-IV could block the increased adipogenesis of BMSCs after FAC treatment. We intraperitoneally injected mice with 250 mg·kg iron dextran, with or without ASI-IV (40 mg·kg ), for 4 weeks. ASI-IV inhibited the iron loading-induced bone loss of these mice. Furthermore, ASI-IV played a protective role in iron loading-induced abnormal differentiation of BMSCs by regulating iron homeostasis and metabolism. In summary, our study suggesteds that ASI-IV might have potentials for development into a novel therapeutic strategy for the treatment of iron loading-induced abnormal differentiation of BMSCs and osteoporosis.
铁超负荷已被报道为细胞发育过程中的一种常见应激，这可能与骨丢失和骨质疏松症有关。黄芪甲苷（ASI-IV）是一种从黄芪中提取的纯化合物，已被报道具有心脏保护、抗炎、抗氧化、抗哮喘和抗癌作用。本研究旨在探讨 ASI-IV 是否可以逆转铁超负荷诱导的骨髓间充质干细胞（BMSCs）活力、增殖、多能性和成骨作用抑制，并促进其成脂分化。使用柠檬酸铁铵（FAC）刺激铁超负荷条件。结果表明，ASI-IV 可改善 FAC 诱导的 BMSCs 活力、增殖、多能性和成骨作用降低。此外，ASI-IV 可阻止 FAC 处理后 BMSCs 成脂分化增加。我们通过腹腔注射 250mg·kg 右旋糖酐铁，同时或不给予 ASI-IV（40mg·kg），对小鼠进行 4 周处理。ASI-IV 抑制了这些小鼠的铁超负荷诱导的骨丢失。此外，ASI-IV 通过调节铁平衡和代谢在铁超负荷诱导的 BMSCs 异常分化中发挥保护作用。综上所述，我们的研究表明，ASI-IV 可能具有开发为治疗铁超负荷诱导的 BMSCs 异常分化和骨质疏松症的新型治疗策略的潜力。
